Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 50

Sort by

Sort Order Select

Journal Articles

Role of Lama4 Expression in Bone Marrow Niche for the Progression and Treatment Response of Chronic Myeloid Leukemia

Alma Mansson, Huan Cai, Juan Pablo Medina Giménez, Leif Stenke, Hong Qian

Blood (2023) 142 (Supplement 1): 1786.

https://doi.org/10.1182/blood-2023-173844

Published: 2023

Journal Articles

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

Blood (2023) 142 (1): 73–89.

https://doi.org/10.1182/blood.2022016896

Published: 2023

Includes: Supplemental data

Journal Articles

XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use

Hans Lennernäs, Charlotta Liljebris, Magnus Brisander, Gérald Jesson, Per Andersson, Gunnar Larfors, Leif Stenke

Blood (2022) 140 (Supplement 1): 9652–9653.

https://doi.org/10.1182/blood-2022-169884

Published: 2022

Journal Articles

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

Gunnar Larfors, Hans Lennernäs, Charlotta Liljebris, Magnus Brisander, Gérald Jesson, Per Andersson, Leif Stenke

Blood (2022) 140 (Supplement 1): 6769–6770.

https://doi.org/10.1182/blood-2022-156487

Published: 2022

Journal Articles

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Michael W. Deininger, Tim H Brummendorf, Jeffrey H. Lipton, Dragana Milojkovic, Leif Stenke, Eric Leip, Simon Purcell, Andrea Viqueira, Jorge E. Cortes

Blood (2022) 140 (Supplement 1): 3913–3915.

https://doi.org/10.1182/blood-2022-163276

Published: 2022

Journal Articles

Overall Survival and Adverse Events in 378 Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia - a Swedish Register-Based Nationwide Study

Torsten Dahlen, Gustaf Edgren, Leif Stenke, Jingcheng Zhao

Blood (2021) 138 (Supplement 1): 3750.

https://doi.org/10.1182/blood-2021-148537

Published: 2021

Journal Articles

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

Delphine Rea, Slawomira Kyrcz-Krzemien, Paolo Sportoletti, Jiří Mayer, Arpad Illes, Anna Angona, Alexander Kiani, Aude Charbonnier, Theodoros Marinakis, Leif Stenke, Ansgar Weltermann, Seema Shah, Sharon Supekar, Luigi Di Caprio, Michele Baccarani

Blood (2021) 138 (Supplement 1): 635.

https://doi.org/10.1182/blood-2021-145611

Published: 2021

Journal Articles

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Susanne Saussele, MD, Johan Richter, MD PhD, Joelle Guilhot, PhD, Henrik Hjorth-Hansen, MD, Antonio Medina de Almeida, MD PhD, Jeroen J. W. M. Janssen, MD, Jiri Mayer, Prof, MD SCs, Perttu Koskenvesa, MD, Panayiotis Panayiotidis, MD PhD, Ulla Olsson-Strömberg, MD PhD, Juan Luis Steegmann, MD PhD, Hanne Vestergaard, MD, Hans Ehrencrona, MD PhD, Veli Kairisto, Kateřina Machová Poláková, PhD, Martin Müller, MD, Satu Mustjoki, MDPhD, Marc G. Berger, MD PhD, Philippe Rousselot, Martine Escoffre-Barbe, MD, Gabriel Etienne, MD PhD, Jolanta Dengler, MD, Françoise Rigal-Huguet, MD, Nikolas von Bubnoff, MD, Hana Klamova, MD, Edgar Faber, MD, François Guilhot, MD, Kourosh Lotfi, MD, Delphine Rea, MD, Tim H. Brümmendorf, MD, Gorgine de Greef, MD, Leif Stenke, MD, Franck Emmanuel Nicolini, MD PhD, Laurence Legros, MD PhD, Andreas Burchert, MD, Jaroslava Voglová, MD, Aude Charbonnier, MD, Emmanuel Gyan, MDPhD, Maria-Elisabeth Goebeler, MD, Peter E. Westerweel, MD, Andreas Hochhaus, MD, Markus Pfirrmann, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 313.

https://doi.org/10.1182/blood.V130.Suppl_1.313.313

Published: 2017

Journal Articles

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

Rebecca Warfvinge, Linda Geironson, Mikael N. E. Sommarin, Stefan Lang, Christine Karlsson, Teona Roschupkina, Leif Stenke, Jesper Stentoft, Ulla Olsson-Strömberg, Henrik Hjorth-Hansen, Satu Mustjoki, Shamit Soneji, Johan Richter, Göran Karlsson

Blood (2017) 129 (17): 2384–2394.

https://doi.org/10.1182/blood-2016-07-728873

Published: 2017

Includes: Supplemental data

Journal Articles

No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries

Niklas Gunnarsson, MD, Martin Höglund, MD PhD, Leif Stenke, MD PhD, Fredrik Sandin, MSc, Magnus Bjorkholm, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevärn, MD, Ulla Olsson-Strömberg, MD PhD, Hans Wadenvik, MD PhD, Johan Richter, MD, Anders Själander, MD PhD

Blood (2016) 128 (22): 1896.

https://doi.org/10.1182/blood.V128.22.1896.1896

Published: 2016

Journal Articles

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Blood (2016) 128 (22): 627.

https://doi.org/10.1182/blood.V128.22.627.627

Published: 2016

Journal Articles

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Anna Kreutzman, PhD, Perttu Koskenvesa, MD, Kasanen Tiina, Ulla Olsson-Strömberg, MD PhD, Jesper Stentoft, MD PhD, Leif Stenke, MD PhD, Lene Udby, MD, Bjorn T. Gjertsen, MD PhD, Kourosh Lotfi, MD, Berit Markevän, MD PhD, Jeroen Janssen, MD, Tim Brümmendorf, MD, Johan Richter, MD, Henrik Hjorth-Hansen, MD PhD, Satu Mustjoki, MD PhD

Blood (2016) 128 (22): 3069.

https://doi.org/10.1182/blood.V128.22.3069.3069

Published: 2016

Journal Articles

Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Blood (2015) 126 (23): 4022.

https://doi.org/10.1182/blood.V126.23.4022.4022

Published: 2015

Journal Articles

Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Niklas Gunnarsson, MD, Martin Hoglund, MD PhD, Leif Stenke, MD PhD, Solveig Wallberg Jonsson, MD PhD, Fredrik Sandin, PhD, Magnus Bjorkholm, MD PhD, Arta Dreimane, MD PhD, Mats Lambe, MD PhD, Berit Markevarn, MD, Ulla Olsson-Stromberg, MD PhD, Hans Wadenvik, MD PhD, Johan Richter, MD PhD, Anders Sjalander, MD PhD

Blood (2015) 126 (23): 1586.

https://doi.org/10.1182/blood.V126.23.1586.1586

Published: 2015

Journal Articles

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Blood (2015) 126 (23): 343.

https://doi.org/10.1182/blood.V126.23.343.343

Published: 2015

Journal Articles

Modulation of Leukotriene Signaling Affecting Cell Growth in Chronic Myeloid Leukemia: A Key Pathway to Cure?

Elham Yektaei, PhD, Anders Nilsson, PhD, Barbro Näsman-Glaser, MSc, Marja Ekblom, MD PhD, Hong Qian, PhD, Olof Rådmark, PhD, Ana Zovko, PhD, Lena Kanter, MD PhD, Jonas Wallvik, MD PhD, Leif Stenke, MD PhD

Blood (2015) 126 (23): 5137.

https://doi.org/10.1182/blood.V126.23.5137.5137

Published: 2015

Journal Articles

Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia

Monika Dolinska, Johannis Klang, Pingnan Xiao, MD, Andranik Durgaryan, Lakshmi Sandhow, Anne-Sofie Johansson, Makoto Kondo, Stefan Deneberg, MD, PhD, Johanna Ungerstedt, Associate Professor, Katarina Le Blanc, MD, PhD, Leif Stenke, MD PhD, Marja Ekblom, Ulla Stromberg, MDPhD, Satu Mustjoki, MD PhD, Soren Lehmann, MD PhD, Hong Qian, PhD

Blood (2015) 126 (23): 2398.

https://doi.org/10.1182/blood.V126.23.2398.2398

Published: 2015

Journal Articles

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Henrik Hjorth-Hansen, MD PhD, Jesper Stentoft, Johan Richter, MD PhD, Perttu Koskenvesa, MD, Arta Dreimane, MD, Kimmo Porkka, MD PhD, Tobias Gedde-Dahl, MDPhD, Bjorn Gjertsen, MD PhD, Franz X. Gruber, MDPhD, Martin Hoglund, MD PhD, Anna Lubking, MD, Kristina Myhr-Eriksson, MD, Berit Markevärn, Hanne Vestergaard, MDPhD, Ole Weis Bjerrum, MDPhD, Leif Stenke, MDPhD, Satu Mustjoki, MD PhD, Ulla Stromberg, MDPhD

Blood (2015) 126 (23): 477.

https://doi.org/10.1182/blood.V126.23.477.477

Published: 2015

Journal Articles

Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries

Torsten Dahlén, MD, Gustaf Edgren, MD PhD, Martin Höglund, MD PhD, Mats Lambe, MD PhD, Magnus Björkholm, MD PhD, Fredrik Sandin, PhD, Anders Själander, MD PhD, Johan Richter, MD PhD, Lotta Ohm, MD PhD, Magnus Bäck, MD PhD, Leif Stenke, MD PhD

Blood (2014) 124 (21): 3134.

https://doi.org/10.1182/blood.V124.21.3134.3134

Published: 2014

Journal Articles

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Blood (2014) 124 (21): 812.

https://doi.org/10.1182/blood.V124.21.812.812

Published: 2014

NARROW

Role of Lama4 Expression in Bone Marrow Niche for the Progression and Treatment Response of Chronic Myeloid Leukemia

Characterization of the bone marrow niche in patients with chronic myeloid leukemia identifies CXCL14 as a new therapeutic option

XS004 Dasatinib (XS004) Improves Variability and Bioavailability in Humans Using Amorphous Solid Dispersion Formulation of Dasatinib with Potential Implications for Its Clinical Use

Comedication of Proton Pump Inhibitors and Dasatinib Is Common in CML but XS004, a Novel Amorphous Solid Dispersion Formulation of Dasatinib, Provides Improved Uptake and Low pH-Dependency, Minimizing Unwanted Drug-Drug Interactions

Efficacy and Safety of Bosutinib Vs Imatinib By Charlson Comorbidity Index in Newly Diagnosed Patients with Chronic Myeloid Leukemia

Overall Survival and Adverse Events in 378 Ibrutinib-Treated Patients with Chronic Lymphocytic Leukemia - a Swedish Register-Based Nationwide Study

Treatment-Free Remission (TFR) after Two Different Durations of Nilotinib Consolidation in Patients with Chronic Myeloid Leukemia (CML) Previously Treated with Imatinib: Enestpath Study Results

"Duration of Deep Molecular Response" Has Most Impact on the Success of Cessation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia - Results from the EURO-SKI Trial

Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML

No Increased Prevalence of Malignancies Among First-Degree Relatives of Patients with Chronic Myeloid Leukemia - Data from Population-Based Swedish Registries

Effects of Dasatinib and Interferon-α Combination Treatment on the Immune System in CML

Immunological Monitoring of CML Patients during First-Line Bosutinib and Imatinib Treatment

Single-Cell Immune Signatures in Patients with Chronic Phase Chronic Myeloid Leukemia (CML) Treated with Nilotinib: An ENEST1st Sub Study

Increased Prevalence of Prior Malignancies and Autoimmune Diseases in Patients Diagnosed with Chronic Myeloid Leukemia

Mature, Adaptive-like CD56 DIM NK Cells in Chronic Myeloid Leukemia Patients in Treatment Free Remission

Modulation of Leukotriene Signaling Affecting Cell Growth in Chronic Myeloid Leukemia: A Key Pathway to Cure?

Phenotypic and Functional Alterations of Bone Marrow Mesenchymal Stem and Progenitor Cells in Chronic Myeloid Leukemia

Safety and Efficacy of Addition of Pegylated Interferon alpha2b to Standard Dose Dasatinib in Newly Diagnosed Chronic Phase CML Patients

Increased Risk of Cardiovascular Events Associated with TKI Treatment in Chronic Phase Chronic Myeloid Leukemia. Data from Swedish Population-Based Registries

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only